Excelra Degrader Discovery Database

Targeting the undruggable proteome

Excelra's Degrader Discovery Database is a comprehensive suite of compounds, ligases, drugs, and targets that provides a powerful data resource in various stages of degrader development for the entire drug discovery value chain.

Early Drug Discovery

Preclinical Devlopment

Clinical Development

Knowledgebase to facilitate your ideas to impact

Compounds

- Structural information
  (SMILES,Molecular formula, Molecular weight, etc.)
- Physicochemical properties
  (Permeability, Solubility, Partition coefficient, Hydrogen bond donor/acceptor, etc.)

Ligases

- Ligase expression and localization
- Cognate E1 and E2 partners

**Degrader Discovery Database**

Diseases

- Therapeutic areas
- Disease Identifiers

Targets

- Target expression and localization
- Ubiquitination sites and status

Managing data complexity

20,000+ Degraders	**1700+** Tragets	**400+** Diseases	**500+** E3 Ligases

Data Coverage

15+ Phisico-chemical properties	**100+** Linkers	**5** E1 Ligases	**35+** E2 Ligases

Leveraging enormous data from multiple sources

Partnering with you in the journey–Transformation from researchers to pioneers

Target identification

Identify proteins which play a pivotal role in disease pathophysiology and are amenable for targeted ablation

Compound optimizaion

Use information (physicochemical properties,linker details, etc.) to design compounds with improved properties and potency to optimize the portfolio

E3 ligase identification

Toolbox to identify and shortlist novel E3 ligase which can be employed to design custom degraders

Excelra advantage

Empowering you to discover new opportunities

Custom solutions

Global clientele

Advanced analytics

Domain expertise

Actionable insights

Unlock the hidden opportunities in targeted protein degradation space by visiting our website:
https://www.excelra.com/discovery/targeted-protein-degradation/

excelra

About Excelra

Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market. The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyse large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discovery and development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 150 global clients, including 15 of the top 20 large Pharma companies.

marketing@excelra.com

www.excelra.com